Advertisement
Screener

BioXcel Therapeutics, Inc. (BTAI) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

BioXcel Therapeutics, Inc. Operating Cash Flow

BioXcel Therapeutics, Inc. (BTAI) reported Operating Cash Flow of -$17.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13

  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.10M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$11.81M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.21M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$18.79M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$57.62M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$72.03M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$155.01M.
  • BioXcel Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$135.34M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$6.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$17.91M
10-Q · filed 2026-08-13
-$32.12M
derived: sum of 3 quarters · filed 2026-08-13
-$50.90M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$11.81M
10-Q · filed 2026-05-15
-$26.02M
derived: sum of 2 quarters · filed 2026-05-15
-$44.81M
derived: sum of 3 quarters · filed 2026-05-15
-$57.38M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$14.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
-$33.00M
derived: sum of 2 quarters · filed 2026-03-27
-$45.57M
derived: sum of 3 quarters · filed 2026-08-13
-$57.62M
10-K · filed 2026-03-27
2025-09-30-$18.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$31.36M
derived: sum of 2 quarters · filed 2026-08-13
-$43.41M
10-Q · filed 2025-11-12
-$58.21M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$12.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$24.62M
10-Q · filed 2026-08-13
-$39.43M
derived: sum of 3 quarters · filed 2026-08-13
-$55.77M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$12.04M
10-Q · filed 2026-05-15
-$26.85M
derived: sum of 2 quarters · filed 2026-05-15
-$43.19M
derived: sum of 3 quarters · filed 2026-05-15
-$66.36M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$14.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
-$31.15M
derived: sum of 2 quarters · filed 2026-03-27
-$54.32M
derived: sum of 3 quarters · filed 2026-03-27
-$72.03M
10-K · filed 2026-03-27
2024-09-30-$16.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$39.51M
derived: sum of 2 quarters · filed 2025-11-12
-$57.22M
10-Q · filed 2025-11-12
-$84.08M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$23.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$40.88M
10-Q · filed 2025-08-12
-$67.74M
derived: sum of 3 quarters · filed 2025-08-12
-$105.33M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$17.71M
10-Q · filed 2025-05-12
-$44.57M
derived: sum of 2 quarters · filed 2025-05-12
-$82.15M
derived: sum of 3 quarters · filed 2025-05-12
-$120.36M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$26.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
-$64.45M
derived: sum of 2 quarters · filed 2025-03-28
-$102.65M
derived: sum of 3 quarters · filed 2025-03-28
-$155.01M
10-K · filed 2025-03-28
2023-09-30-$37.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$75.79M
derived: sum of 2 quarters · filed 2024-11-14
-$128.14M
10-Q · filed 2024-11-14
-$166.78M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$38.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
-$90.56M
10-Q · filed 2024-08-06
-$129.20M
derived: sum of 3 quarters · filed 2024-08-06
-$160.38M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31-$52.35M
10-Q · filed 2024-05-09
-$90.99M
derived: sum of 2 quarters · filed 2024-05-09
-$122.18M
derived: sum of 3 quarters · filed 2024-05-09
-$155.28M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$38.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22
-$69.83M
derived: sum of 2 quarters · filed 2024-03-22
-$102.93M
derived: sum of 3 quarters · filed 2024-03-22
-$135.34M
10-K · filed 2024-03-22
2022-09-30-$31.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$64.29M
derived: sum of 2 quarters · filed 2023-11-14
-$96.70M
10-Q · filed 2023-11-14
-$116.63M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$33.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$65.52M
10-Q · filed 2023-08-14
-$85.45M
derived: sum of 3 quarters · filed 2023-08-14
-$105.65M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$32.41M
10-Q · filed 2023-05-09
-$52.34M
derived: sum of 2 quarters · filed 2023-05-09
-$72.54M
derived: sum of 3 quarters · filed 2023-05-09
-$94.93M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$19.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
-$40.13M
derived: sum of 2 quarters · filed 2023-03-16
-$62.51M
derived: sum of 3 quarters · filed 2023-03-16
-$82.15M
10-K · filed 2023-03-16
2021-09-30-$20.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$42.58M
derived: sum of 2 quarters · filed 2022-11-14
-$62.22M
10-Q · filed 2022-11-14
-$82.49M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$22.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$42.02M
10-Q · filed 2022-08-11
-$62.29M
derived: sum of 3 quarters · filed 2022-08-11
-$81.39M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$19.64M
10-Q · filed 2022-05-09
-$39.91M
derived: sum of 2 quarters · filed 2022-05-09
-$59.01M
derived: sum of 3 quarters · filed 2022-05-09
-$73.83M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31-$20.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
-$39.37M
derived: sum of 2 quarters · filed 2022-03-11
-$54.19M
derived: sum of 3 quarters · filed 2022-03-11
-$66.35M
10-K · filed 2022-03-11
2020-09-30-$19.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$33.92M
derived: sum of 2 quarters · filed 2021-11-10
-$46.08M
10-Q · filed 2021-11-10
-$54.00M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$14.82M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
-$26.98M
10-Q · filed 2021-08-10
-$34.90M
derived: sum of 3 quarters · filed 2021-08-10
-$42.38M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31-$12.16M
10-Q · filed 2021-05-10
-$20.08M
derived: sum of 2 quarters · filed 2021-05-10
-$27.56M
derived: sum of 3 quarters · filed 2021-05-10
-$33.59M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31-$7.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$15.40M
derived: sum of 2 quarters · filed 2021-03-12
-$21.43M
derived: sum of 3 quarters · filed 2021-03-12
-$27.10M
10-K · filed 2021-03-12
-$27.28M
10-K · filed 2020-03-09
2019-09-30-$7.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
-$13.51M
derived: sum of 2 quarters · filed 2020-11-12
-$19.18M
10-Q · filed 2020-11-12
-$19.36M
10-Q · filed 2019-11-14
-$23.52M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$6.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
-$11.70M
10-Q · filed 2020-08-14
-$16.04M
derived: sum of 3 quarters · filed 2020-08-14
-$19.22M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31-$5.67M
10-Q · filed 2020-05-12
-$10.01M
derived: sum of 2 quarters · filed 2020-05-12
-$13.20M
derived: sum of 3 quarters · filed 2020-05-12
-$18.17M
derived: sum of 4 quarters · filed 2020-05-12
2018-12-31-$4.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
-$7.53M
derived: sum of 2 quarters · filed 2020-03-09
-$12.50M
derived: sum of 3 quarters · filed 2020-03-09
-$13.51M
10-K · filed 2020-03-09
2018-09-30-$3.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14
-$8.16M
derived: sum of 2 quarters · filed 2019-11-14
-$9.17M
10-Q · filed 2019-11-14
-$10.27M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$4.97M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
-$5.98M
10-Q · filed 2019-08-06
-$7.08M
derived: sum of 3 quarters · filed 2019-08-06
-$7.40M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31-$1.01M
10-Q · filed 2019-05-07
-$2.11M
derived: sum of 2 quarters · filed 2019-05-07
-$2.43M
derived: sum of 3 quarters · filed 2019-05-07
-$2.78M
derived: sum of 4 quarters · filed 2019-05-07
2017-12-31-$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
-$1.42M
derived: sum of 2 quarters · filed 2019-03-12
-$1.76M
derived: sum of 3 quarters · filed 2019-03-12
-$2.20M
10-K · filed 2019-03-12
2017-09-30-$322.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
-$667.00K
derived: sum of 2 quarters · filed 2018-11-09
-$1.10M
10-Q · filed 2018-11-09
2017-06-30-$345.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$776.00K
10-Q · filed 2018-08-08
2017-03-31-$431.00K
10-Q · filed 2018-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
ORAGENICS INC (OGEN)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02